Capricor Therapeutics, Inc.
CAPR
$31.11
$0.210.68%
NASDAQ
| 12/31/2025 | 09/30/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | 13.62% | -7.66% | |||
| Gross Profit | -13.62% | 7.66% | |||
| SG&A Expenses | 1.66% | 4.46% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 10.93% | -5.18% | |||
| Operating Income | -10.93% | 5.18% | |||
| Income Before Tax | -22.79% | 5.17% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -22.79% | 5.17% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -22.79% | 5.17% | |||
| EBIT | -10.93% | 5.18% | |||
| EBITDA | -11.11% | 5.30% | |||
| EPS Basic | -14.90% | 5.19% | |||
| Normalized Basic EPS | -14.95% | 5.22% | |||
| EPS Diluted | -14.90% | 5.19% | |||
| Normalized Diluted EPS | -14.95% | 5.22% | |||
| Average Basic Shares Outstanding | 6.86% | 0.02% | |||
| Average Diluted Shares Outstanding | 6.86% | 0.02% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||